What is KPV peptide?
5 min read · Updated August 2026 · MY PEPTIDES Research Team
Key facts
KPV is a tripeptide of lysine, proline and valine, corresponding to residues 11–13 at the C-terminus of α-melanocyte-stimulating hormone (α-MSH). It is the smallest fragment of that hormone still studied for melanocortin-associated activity, which is precisely why researchers use it: a three-residue peptide is simpler to synthesise, easier to characterise and avoids the pigmentation-related signalling associated with the full-length hormone. Laboratory work examines melanocortin-linked signalling networks and downstream processes relevant to inflammatory regulation, covering both receptor-associated and receptor-independent mechanisms, transcriptional responses and peptide stability. Because it is so short, KPV is also used as a model compound for studying how small peptides behave in solution and how quickly they degrade. Findings vary with concentration, exposure and model system. MY PEPTIDES supplies KPV as a pre-mixed 12mg solution with a batch Certificate of Analysis, refrigerated at 2–8°C, and it is also one of the four compounds in the KLOW blend. Supplied strictly for in-vitro laboratory research — not for human or veterinary use, and carrying no therapeutic claims.
KPV is a tripeptide — three amino acids, lysine-proline-valine — corresponding to residues 11–13 at the C-terminal end of α-melanocyte-stimulating hormone (α-MSH). It is among the shortest peptides in common laboratory use, and that brevity is the point.
Research use only. This page describes what KPV is and what published laboratory research examines. It does not describe dosing or administration, is not guidance for use in humans or animals, and makes no therapeutic claims.
Why a fragment rather than the whole hormone
α-MSH is a 13-residue hormone with a wide range of signalling activity, including the melanocortin signalling associated with pigmentation. For a researcher interested only in a subset of that activity, the full hormone is a blunt instrument: it does too many things at once to isolate any one of them.
KPV is the C-terminal fragment retained in that work. Using it instead of α-MSH has three practical advantages:
- Specificity — it narrows the range of signalling under investigation
- Synthesis — a three-residue peptide is straightforward to make and to characterise analytically
- Interpretation — fewer variables makes results easier to attribute
This is a common pattern in peptide research. TB-500, for instance, is a fragment of thymosin beta-4 rather than the whole protein, for much the same reasons.
What the research examines
Published work on KPV concentrates on melanocortin-linked signalling and the downstream processes connected to inflammatory regulation. Studies typically address:
- Receptor-associated mechanisms — signalling through melanocortin receptors
- Receptor-independent mechanisms — activity that does not appear to require receptor binding, which is a notable and much-discussed feature of the fragment
- Transcriptional responses — changes in gene expression in cultured cells
- Peptide stability — how the compound behaves in solution over time
That last one deserves emphasis. Because KPV is only three residues long, it is used as a model compound in its own right: work on short-peptide behaviour, degradation kinetics and stability often uses it precisely because it is small and well characterised, independent of any interest in melanocortin signalling.
As with any in-vitro literature, outcomes vary considerably with concentration, exposure time and the model system chosen, and cell-culture results do not transfer straightforwardly to whole organisms.
KPV and the KLOW blend
KPV is the "K" in KLOW — the four-compound blend that also contains GHK-Cu, BPC-157 and TB-500, at 80mg total. Researchers use pre-combined sets like this to study several compounds with distinct mechanisms under one set of conditions, rather than running four separate preparations.
The blend makes no claim about combined activity — the compounds are grouped as a practical convenience. Our KLOW guide breaks down the composition.
How it is supplied
KPV is supplied as a pre-mixed 12mg solution — no reconstitution needed — with a batch-specific Certificate of Analysis recording identity and purity by HPLC. Store refrigerated at 2–8°C.
If you are working out concentrations from a reconstituted vial, the peptide calculator handles the arithmetic.
KPV Peptide
Available now from MY PEPTIDES — 99%+ purity, COA with every order, fast UK dispatch.
Frequently asked questions
- What is KPV peptide?
- KPV is a tripeptide of lysine, proline and valine, corresponding to residues 11–13 of α-melanocyte-stimulating hormone (α-MSH). It is used in laboratory research to study melanocortin-linked signalling and inflammatory regulation, and as a model compound for short-peptide behaviour. Supplied for in-vitro research use only.
- What does KPV stand for?
- The three amino acids it contains, in sequence: lysine (K), proline (P) and valine (V). Peptides are frequently named by their single-letter amino-acid codes, which is why the name is simply the sequence itself.
- How is KPV different from α-MSH?
- α-MSH is the full 13-residue hormone; KPV is just its final three residues. Researchers use the fragment when they want to narrow the range of signalling under study — the whole hormone carries additional activity, including pigmentation-related melanocortin signalling, which adds variables to an experiment.
- Is KPV the same as the KLOW blend?
- No. KPV is a single compound; KLOW is a four-compound blend containing GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg) and TB-500 (10mg), 80mg in total. KPV is one of the four, and is also available on its own as a 12mg vial.
- How should KPV be stored?
- Refrigerated at 2–8°C. We supply it as a pre-mixed solution rather than a lyophilised powder, so there is no reconstitution step. Our guide on storing research peptides covers handling and solution stability in more detail.